ArticleLiver international : official journal of the International Association for the Study of the Liver2015
Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- Modeling hepatitis D virus kinetics during bulevirtide monotherapy: challenges and solutions.ArXiv · 2026Article
- Modeling predicts shortening of DAA treatment duration to 5 weeks in individuals with recent or chronic infection with HCV RNA negativity at day 7 on treatment.The Journal of infectious diseases · 2026Article
- A Comprehensive Review on the Antibacterial, Antifungal, Antiviral, and Antiparasitic Potential of Silybin.Antibiotics (Basel, Switzerland) · 2024Review
- Hepatitis D Virus and HBsAg Dynamics in the era of new Antiviral Treatments.Current gastroenterology reports · 2023Review
- Advances in Parameter Estimation and Learning from Data for Mathematical Models of Hepatitis C Viral Kinetics.Mathematics (Basel, Switzerland) · 2022Article
- Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration.Open forum infectious diseases · 2022Article
- Machine learning for mathematical models of HCV kinetics during antiviral therapy.Mathematical biosciences · 2022Article
- Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study.Scientific reports · 2020Article
- Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration.The Journal of infectious diseases · 2020Article
- Efficient Methods for Parameter Estimation of Ordinary and Partial Differential Equation Models of Viral Hepatitis Kinetics.Mathematics (Basel, Switzerland) · 2020Article
- Modeling based response guided therapy in subjects with recent hepatitis C infection.Antiviral research · 2020Article
- A Parameter Estimation Method for Multiscale Models of Hepatitis C Virus Dynamics.Bulletin of mathematical biology · 2019Article
- Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin.Viruses · 2019Article
- Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2019Article
- Antiviral Activities of Silymarin and Derivatives.Molecules (Basel, Switzerland) · 2019Review
- Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics.Mathematical biosciences · 2018Article
- A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics.Frontiers in applied mathematics and statistics · 2017Article
- Modeling HCV cure after an ultra-short duration of therapy with direct acting agents.Antiviral research · 2017Article
- Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years.Molecules (Basel, Switzerland) · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
BACKGROUND &
aimsIntravenous silibinin (SIL) is a potent antiviral agent against hepatitis C virus (HCV) genotype-1. In this proof of concept case-study we tested: (i) whether interferon-alfa (IFN)-free treatment with SIL plus ribavirin (RBV) can achieve sustained virological response (SVR); (ii) whether SIL is safe and feasible for prolonged duration of treatment and (iii) whether mathematical modelling of early on-treatment HCV kinetics can guide duration of therapy to achieve SVR.
methodsA 44 year-old female HCV-(genotype-1)-infected patient who developed severe psychiatric adverse events to a previous course of pegIFN+RBV, initiated combination treatment with 1200 mg/day of SIL, 1200 mg/day of RBV and 6000 u/day vitamin D. Blood samples were collected frequently till week 4, thereafter every 1-12 weeks until the end of therapy. The standard biphasic mathematical model with time-varying SIL effectiveness was used to predict the duration of therapy to achieve SVR.
resultsBased on modelling the observed viral kinetics during the first 3 weeks of treatment, SVR was predicted to be achieved within 34 weeks of therapy. Provided with this information, the patient agreed to complete 34 weeks of treatment. IFN-free treatment with SIL+RBV was feasible, safe and achieved SVR (week-33).
conclusionsWe report, for the first time, the use of real-time mathematical modelling of HCV kinetics to individualize duration of IFN-free therapy and to empower a patient to participate in shared decision making regarding length of treatment. SIL-based individualized therapy provides a treatment option for patients who do not respond to or cannot receive other HCV agents and should be further validated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.